Effect of Pre-Procedure Clopidogrel With Iliac Vein Stenting in Non-Thrombotic Vein Lesions.

Abstract

OBJECTIVES:

Iliac vein stenting is a relatively new procedure in the treatment of chronic venous insufficiency. Research has shown that it is a safe and effective form of treatment, however, one of the well-known risks is in-stent thrombosis. We hypothesize that a single 75 mg dose of Clopidogrel the night prior to the procedures along with a 3-month regimen post-op would decrease the 30-day thrombosis rate.

METHODS:

A retrospective study was performed on 3,518 patients from September 2012 to August 2018 who received an iliofemoral stent. Patients were broken down into 2 main groups: those given Clopidogrel post-stent and those given Clopidogrel both pre- and post-stent. In our practice, we prescribe a 3-month course of Clopidogrel after iliac vein stenting. Patients were also checked for any anticoagulant medications pre- and/or post-stent. The 30-day thrombosis rates were recorded for each patient.

RESULTS:

1,205 patients received Clopidogrel pre-procedurally and post-procedurally, 1,941 patients received Clopidogrel only post-procedurally. 372 patients were excluded from the study because they were on other anti-coagulant medications. Mean follow-up for this cohort was 17 months. 112 total patients developed some degree of 30 day in-stent thrombosis (3.6%). 74 patients developed a complete thrombosis of the stent and 38 developed a partial (≤60% occlusion) thrombosis. Of the 1,205 patients who were on clopidogrel pre-stenting, 28 had a complete thrombosis and 10 had a partial in-stent thrombosis. Of the 1,941 patients on Clopidogrel only post-stenting, 46 had a complete thrombosis and 28 had a partial in-stent thrombosis. Using the Chi-squared test, there were no statistically significant differences between the group of patients receiving Clopidogrel pre- and post-stent vs. just post-stent with respect to 30-day any degree of thrombosis rates (complete and partial thrombosis) (p = .33). Using the Chi-squared test, there were no statistically significant differences between the group of patients receiving Clopidogrel pre- and post-stent vs. just post-stent with respect to 30-day complete thrombosis rates (p = .93).

CONCLUSIONS:

There appears to be no statistical difference in 30-day thrombosis rates between those receiving Clopidogrel the night prior vs. those who do not receive Clopidogrel the night prior. Therefore, we conclude that it is not necessary to give this single dose the night prior to iliac vein stenting procedures.

• Authors: Pavel Kibrik, Michael Arustamyan, Ahmad Alsheekh, Yuriy Ostrozhynskyy, Vera Rabinovich, Natalie Marks, Anil Hingorani, Enrico Ascher
• Journal: Vascular and endovascular surgery (Vasc Endovascular Surg) Vol. 55 Issue 5 Pg. 448-451 (Jul 2021) ISSN: 1938-9116 [Electronic] United States
• PMID: 33602039 (Publication Type: Journal Article)

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel

Topics

• Adult
• Aged
• Aged, 80 and over
• Chronic Disease
• Clopidogrel (administration & dosage, adverse effects)
• Drug Administration Schedule
• Endovascular Procedures (adverse effects, instrumentation)
• Female
• Humans
• Iliac Vein (diagnostic imaging, physiopathology)
• Male
• Middle Aged
• Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
• Retrospective Studies
• Risk Assessment
• Risk Factors
• Stents
• Time Factors
• Treatment Outcome
• Venous Insufficiency (diagnostic imaging, physiopathology, therapy)
• Venous Thrombosis (etiology, prevention & control)
• Young Adult